Antilactoferrin antibody in systemic lupus erythematosus

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Lactoferrin is a neutrophil protein involved in immune responses.
• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse manifestations.
• The role of lactoferrin antibodies (LF-ab) in SLE pathogenesis and activity is not fully understood.

Purpose of the Study:

• To investigate the prevalence of antibodies against human lactoferrin (LF-ab) in patients with systemic lupus erythematosus (SLE).
• To determine the correlation between LF-ab positivity and clinical features, disease duration, and activity in SLE patients.
• To evaluate LF-ab as a potential biomarker for monitoring SLE.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to detect LF-ab in 79 SLE patients meeting ARA classification criteria.
• Clinical data, including disease duration and manifestations, were collected and analyzed.
• Immunofluorescence was performed on neutrophils to assess antibody binding patterns.

Main Results:

• Elevated levels of LF-ab were detected in 39.2% of SLE patients.
• A significant correlation was observed between LF-ab positivity and longer disease duration (P < 0.05).
• Clinical flare was more common in LF-ab positive patients. Increased incidence of lymphadenopathy and crescentic glomerulonephritis was noted in this group.

Conclusions:

• LF-ab positivity is associated with increased disease activity and duration in SLE.
• LF-ab may serve as a useful marker for monitoring disease activity in systemic lupus erythematosus.
• Further research is needed to elucidate the precise role of LF-ab in SLE pathogenesis.